|
The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Affymetrix Inc. granted bioMerieux long-term and comprehensive access to its GeneChip technology to develop and market in vitro diagnostic tests for breast cancer, as well as an option to expand the agreement into other cancer areas. The agreement gives bioMerieux non-exclusive rights to Affymetrix' patented arrays, instrumentation systems and future improvements to these key technologies. Financial terms of the agreement were not disclosed. Caliper Life Sciences, Inc. has issued Affymetrix Inc. a non-exclusive license to use a portion of Caliper's microfluidics patent estate with Affymetrix' GeneChip microarray technologies in all areas of application, including research, diagnostics and applied genomics applications. The CDC has developed the Genetic Testing Quality Control Materials Program in partnership with the genetics community. The goal of this program is to coordinate a self-sustaining community process to improve the availability of appropriate and verified materials for quality control, proficiency testing, test development, and research. Gen-Probe has developed a prototype urine test for PCA3 gene expression for the diagnosis of prostate cancer. The PCA3 gene is over-expressed only in malignant prostate tissue. Gen-Probe acquired exclusive worldwide diagnostic rights to the PCA3 gene from DiagnoCure in November of 2003. The companies maintain a license and collaboration agreement under which they are developing, and Gen-Probe will market, the APTIMA PCA3 assay. Genelex Corporation markets GeneMedRx a DNA ready version of a software tool used by physicians since 1997 to identify potential drug interactions based on individual patient prescription, over-the-counter, and herbal medicine regimens. Identifying drug interactions is essential to preventing adverse drug reactions. The GeneMedRx database contains entries for 2000 medicines, foods and environmental exposures. The National Geographic Society and IBM launched The Genographic Project, a five-year research initiative that will trace the migratory history of the human species. The project will perform computer analysis of DNA contributed by hundreds of thousands of people, including indigenous peoples and members of the general public, to map how the Earth was populated. PerkinElmer Inc. and JN Macri Technologies, LLC signed a license agreement which gives PerkinElmer rights to manufacture and sell kits for the measurement of free beta human chorionic gonadotrophin (free hCGa) in liquid blood for risk assessment of fetal anomalies during pregnancy. The technology includes reagents used to detect free hCGa and software that utilizes free hCGa measurements to calculate the risk of a fetus having chromosomal abnormalities. Seryx Inc. has developed the Signature Genetics interpretive report designed to assist physicians in customizing drug prescriptions based on an individual patient's unique genetic makeup, as well as to identify drug combinations which can cause harmful interactions. Once a cheek swab and medical history questionnaire are sent to the laboratory, a Signature Genetics report is sent to the physician's office within 15 business days." XDx, Inc. has launched AlloMap, a test for the management of heart transplant patients that identifies the risk of tissue damage and rejection before it occurs and may enable physicians to proactively manage immunosuppressive medications. In addition to current marketing of AlloMap testing for heart transplant rejection and ongoing clinical trials in lung transplant patients, XDx plans to apply the technology to other transplanted organs and various autoimmune disorders.
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
![[HRule Image]](images/div.jpg){kind=small} Send mail to stratcom@pagebleu.com with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: May 6, 2005 |
![[Page Banner Image]](images/hmole.gif){kind=small}
